Advanced in Peripheral T-Cell Lymphoma

Takeshi Hara

Hashima, JP 
Advanced in Peripheral T-Cell Lymphoma
Hashima, JP 
OverviewLocationsClinical Research

Overview

Takeshi Hara practices in Hashima, Japan. Mr. Hara is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Superior Mesenteric Artery Syndrome (SMAS), Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Leg or Foot Amputation, and Thrombectomy.

His clinical research consists of co-authoring 219 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Male

Locations

Hashima, Japan
Other Locations
Gifu-shi, Japan
Tokyo, Japan
Hiroshima, 7348551, Japan
Utsunomiya, Japan
Kyoto, 6048511, Japan
Nagoya, 4648601, Japan
Osaka, Japan
Minami, 7348551, Japan
Kami-kojimbara, Japan
Suita, Japan
Tokai, 4668560, Japan
Kasamatsucho, 5016062, Japan
Akasaka, 1070052, Japan
Kasuga, Japan
Fukuoka, 8160864, Japan
Higashi, 8128582, Japan
Shinjuku, 1600023, Japan
Sakura, Japan
Chuo, Japan
Wakayama, 6408505, Japan
Chiba, Japan
Higashihiroshima, Japan
Iwakuni, Japan
Kasamatsu, Japan
Hara, Japan
St Luke's International Hospital, 9-1 Akashi Cho, Chuo, 1048560, Japan
Tochigi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

219 Total Publications

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.
Journal: Annals of hematology
Published: July 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hara's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 65 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile